Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
(IPF/ILD-PRO Trial)
Trial Summary
What is the purpose of this trial?
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the third phase of the registry begins, the IPF-PRO registry will enroll additional patients with idiopathic pulmonary fibrosis. This IPF-PRO registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) or of another chronic fibrosing interstitial lung disease (ILD) with progressive phenotype established at the enrolling centers. In addition, blood samples and chest image studies will be collected and banked for future research projects.
Research Team
Scott Palmer, MD
Principal Investigator
Duke Clinical Research Institute, Duke University
Eligibility Criteria
Inclusion Criteria
Treatment Details
Interventions
- Blood Sample Collection (Other)
- Data Collection (Other)
- HRCT Image Collection (Other)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Duke University
Lead Sponsor
Mary E. Klotman
Duke University
Chief Executive Officer since 2017
MD from Duke University School of Medicine
Michelle McMurry-Heath
Duke University
Chief Medical Officer since 2020
MD from Duke University School of Medicine
Boehringer Ingelheim
Industry Sponsor